Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle, Suite 801
Coral Gables, FL 33134
Phone: (305) 420-3200Website: https://catalystpharma.com/Careers: catalystpharma.com/careers
Latest news
- FDA Approves Agamree (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
26 October 2023 - Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy
9 January 2023 - Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
27 October 2022 - Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
29 March 2022
Drugs Associated with Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Agamree
Generic name: vamorolone Drug class: glucocorticoids |
||
|
Firdapse
Generic name: amifampridine Drug class: cholinergic muscle stimulants |
3 reviews | 1.0 / 10 |
|
Fycompa
Generic name: perampanel Drug class: AMPA receptor antagonists |
61 reviews | 5.8 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
